Skip to main content

Table 1 Baseline characteristics

From: Switching from TNFα inhibitor to tacrolimus as maintenance therapy in rheumatoid arthritis after achieving low disease activity with TNFα inhibitors and methotrexate: 24-week result from a non-randomized, prospective, active-controlled trial

Parameters TAC + MTX
(n = 34)
TNFi + MTX
(n = 80)
P-value
Age, years 51.3 ± 9.7 50.5 ± 10.9 0.8598
Females, n (%) 31 (91.2) 64 (80.0) 0.1430
Body mass index, kg/m2 23.0 ± 2.5 23.0 ± 2.8 0.9284
Disease duration, months 95.0 ± 50.8 90.3 ± 70.0 0.2797
RF positivity, n (%) 27 (79.4) 65 (81.2) 0.8219
ACPA positivity, n (%) 32 (94.1) 64 (80) 0.0594
Tender joint count (0–68) 0.2 ± 0.7 0.2 ± 0.4 0.2760
Swollen joint count (0–66) 0.1 ± 0.5 0.1 ± 0.3 0.8964
PhGA (VAS, mm) 9.3 ± 10.6 10.0 ± 8.3 0.7022
PGA (VAS, mm) 15.4 ± 14.3 17.3 ± 17.9 0.5827
ESR, mm/h 21.3 ± 14.9 20.6 ± 13.5 0.8092
CRP, mg/dL 0.31 ± 0.48 0.23 ± 0.30 0.2833
DAS28-CRP 1.28 ± 0.48 1.25 ± 0.29 0.6820
HAQ-DI 0.28 ± 0.32 0.43 ± 0.50 0.1097
Larsen score 12.5 ± 19.1 12.1 ± 20.5 0.9190
MTX dose, mg/week 10.0 ± 2.3 10.8 ± 2.9 0.1398
Glucocorticoids, n (%) 16 (47.1) 43 (53.8) 0.5173
  1. Continuous variables are presented as means ± standard deviations unless otherwise indicated. ACPA, anti-citrullinated peptide antibody; CRP, C-reactive protein; DAS28-CRP, Disease Activity Score for 28 joints based on CRP; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; MTX, methotrexate; PhGA, Physician’s Global Assessment of Disease Activity; PGA, Patient’s Global Assessment of Disease Activity; RF, rheumatoid factor; TNFi, tumor necrosis factor inhibitor; VAS, visual analog scale; TAC, tacrolimus